Literature DB >> 3858972

Acid inhibitory characteristics of omeprazole in man.

C Cederberg, G Ekenved, T Lind, L Olbe.   

Abstract

Single-dose studies in man have shown that omeprazole is a potent inhibitor of acid secretion stimulated by betazole, pentagastrin, modified sham-feeding and peptone. The degree of inhibition is dose-dependent and correlates to the area under the plasma omeprazole concentration-time curve. The duration of action of a single oral dose is 2-3 days and not dependent on a sustained plasma concentration of omeprazole. During repeated once-daily administration the level of acid inhibition increases over the first 5 days, after which it stabilises. With once-daily omeprazole treatment it is possible to almost abolish 24-hour intragastric acidity in the majority of DU patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858972     DOI: 10.3109/00365528509095823

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  11 in total

1.  Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

Authors:  L C Baak; J B Jansen; I Biemond; C B Lamers
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.

Authors:  R K Brazzell; P R Mayer; R Dobbs; P J McNamara; R L Teng; J T Slattery
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Influence of chronic omeprazole treatment on gastric endocrine function.

Authors:  H Koop; H Schwarting; A Knorr-Marin; C Willhardt; T Möser; R Arnold
Journal:  Klin Wochenschr       Date:  1987-02-16

Review 5.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

6.  Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.

Authors:  T Lind; C Cederberg; M Olausson; L Olbe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  A comparison of omeprazole and ranitidine for duodenal ulcer in South African patients. A multiracial study.

Authors:  I N Marks; M D Danilewitz; J A Garisch
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

8.  A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.

Authors:  Michio Hongo; Yoshikazu Kinoshita; Ken Haruma
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

9.  Saturable tissue binding and imirestat pharmacokinetics in rats.

Authors:  J Y Chien; C R Banfield; R K Brazzell; P R Mayer; J T Slattery
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

10.  Serum gastrin levels following administration of omeprazole alone or in combination with pirenzepine.

Authors:  A Iwasaki; K Miyazawa; Y Kawamura; Y Sakai; Y Tashiro; K Ito; Y Arakawa; Y Matsuo
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.